Emotional and Behavioral Disorders in Children and Adolescents

INTRODUCTION	
STUDY OBJECTIVES	
	
REASONS FOR DOING THIS STUDY	
	
CONTRIBUTIONS OF THE STUDY	
	
SCOPE OF THE STUDY	
	
METHODOLOGY	
	
INFORMATION SOURCES	
	
ABOUT THE AUTHOR	
	
RELATED BCC REPORTS	
	
BCC ONLINE SERVICES	
	
DISCLAIMER	
	
SUMMARY	
Summary Table:	
WORLDWIDE SALES OF DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Summary Figure:	
WORLDWIDE SALES OF DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
OVERVIEW	
DEFINITIONS OF EMOTIONAL AND/OR BEHAVIOR DISORDERS	
	
DEFINITIONS OF EMOTIONAL AND/OR…(CONTINUED)	
	
TERMINOLOGY	
	
CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS	
	
Table 1 DSM CLASSIFICATIONS* OF EMOTIONAL AND BEHAVIORAL DISORDERS	
	
Table 2 CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS (AS DONE FOR THIS REPORT)	
	
CAUSES OF EMOTIONAL AND BEHAVIOR DISORDERS	
BIOLOGICAL FACTORS	
	
PSYCHOPHYSIOLOGICAL AND GENETIC INFLUENCES	
	
NEUROLOGICAL DYSREGULATION	
	
ENVIRONMENTAL FACTORS	
	
SCHOOL-RELATED FACTORS	
	
PARENT PSYCHOLOGICAL FACTORS	
	
FAMILIAL CONTRIBUTIONS	
	
Divorce, Marital Distress and Violence	
	
Family Adversity and Insularity	
	
Parent-child Interactions	
	
Other Family Characteristics	
	
CHARACTERISTICS OF STUDENTS WITH BEHAVIOR DISORDERS	
	
INTELLIGENCE AND ACHIEVEMENT	
	
Social Skills and Interpersonal Relationships	
	
Antisocial Behavior	
	
Withdrawn Behavior	
	
MANIFESTATIONS OF BEHAVIOR DISORDERS	
	
TYPES OF DISORDERS	
ANXIETY DISORDERS	
	
TYPES OF ANXIETY DISORDERS	
	
CAUSES	
	
SYMPTOMS AND TREATMENT	
	
Psychological Treatments	
	
Psychopharmacological Treatments	
	
Environmental Treatments	
	
SEVERE DEPRESSION	
	
CAUSES	
	
SYMPTOMS AND TREATMENT	
	
Symptoms and Treatment (Continued)	
	
BIPOLAR DISORDER	
	
SYMPTOMS AND TREATMENT	
	
Symptoms and Treatment (Continued)	
	
ATTENTION DEFICIT HYPERACTIVITY DISORDER	
	
SYMPTOMS AND TREATMENT	
	
AUTISM	
	
SYMPTOMS AND TREATMENT	
	
SCHIZOPHRENIA	
	
SYMPTOMS AND TREATMENT	
	
LEARNING DISORDERS	
	
SYMPTOMS AND TREATMENT	
	
CAUSES	
	
CONDUCT DISORDER	
	
SYMPTOMS AND TREATMENT	
	
EATING DISORDERS	
	
SYMPTOMS AND TREATMENTS	
	
DRUG CLASSIFICATION	
CLASSIFICATION BASED ON MECHANISM OF ACTION	
	
BENZODIAZEPINES	
	
Table 3 BENZODIAZEPINES	
	
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)	
	
Table 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)	
	
TRICYCLIC ANTIDEPRESSANTS	
	
Table 5 TRICYCLIC ANTIDEPRESSANTS	
	
ANTIHISTAMINES	
	
Table 6 ANTIHISTAMINES	
	
MAJOR TRANQUILIZERS OR NEUROLEPTICS	
	
Table 7 MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS	
	
MOOD STABILIZERS	
	
Table 8 MOOD STABILIZERS	
	
CNS STIMULANTS	
	
Table 9 CNS STMULANTS	
	
NONSTIMULANTS	
	
Table 10 NONSTMULANTS	
	
ATYPICAL ANTIPSYCHOTICS	
	
Table 11 ATYPICAL ANTIPSYCHOTICS	
	
CLASSIFICATION BASED ON THERAPEUTIC CATEGORY	
	
ANTIANXIETY DRUGS	
	
Table 12 DRUGS USED FOR ANTIANXIETY DISORDERS	
	
Table 12 (CONTINUED)	
	
Clorazepate	
	
Chlordiazepoxide	
	
Chlorpromazine	
	
Clonezepam	
	
Diazepam	
	
Doxipine	
	
Fluoxetine Hydrochloride	
	
Fluphenazine	
	
Fluvoxamine Maleate	
	
Haloperidol	
	
Hydroxyzine	
	
Nortriptyline	
	
Oxazepam	
	
Sertraline Hydrochloride	
	
Thioridazine	
	
Thioxanthene	
	
Trifluperazine	
	
SEVERE DEPRESSION DRUGS	
	
Table 13 DRUGS USED FOR SEVERE DEPRESSION	
	
Amitryptyline	
	
Fluoxetine Hydrochloride	
	
Impramine	
	
Sertraline Hydrochloride	
	
BIPOLAR DISORDER DRUGS	
	
Table 14 DRUGS USED FOR BIPOLAR DISORDER	
	
Lithium	
	
Divalproex	
	
Carbamazepine	
	
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUGS	
	
Table 15 DRUGS USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER	
	
Amphetamines	
	
Dextroamphetamine	
	
Methylphenidate	
	
Pemoline	
	
Atomoxetine Hydrochloride	
	
AUTISTIC DISORDER DRUGS	
	
Table 16 DRUGS USED FOR AUTISTIC DISORDER TREATMENT	
	
Risperidone	
	
SCHIZOPHRENIA DRUGS	
	
Table 17 DRUGS USED FOR SCHIZOPHRENIA	
	
SAFETY, EFFICACY AND REGULATION	
SAFETY AND EFFICACY	
	
SAFETY AND EFFICACY (CONTINUED)	
	
Table 18 LABELLED USE AND APPROVED AGE FOR AGENTS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS	
	
REGULATORY ASPECTS	
	
REGULATORY ASPECTS (CONTINUED)	
	
REGULATORY ASPECTS (CONTINUED)	
	
Table 19 DRUGS RECEIVING A BOXED WARNING, OTHER PRODUCT LABELING CHANGES, AND A MEDICATION GUIDE PERTAINING TO PEDIATRIC SUICIDAL TENDENCIES	
	
DRUG APPROVALS	
	
Table 20 DEVICES AND IMPLANTS APPROVED BY THE FDA 2000-APRIL 2005	
	
INDUSTRY STRUCTURE	
BEHAVIOR AND EMOTIONAL DISORDER DRUG INDUSTRY MARKET BY COMPANY	
	
ANTIANXIETY	
	
Table 21 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)	
	
Figure 1 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)	
	
Antidepressants	
	
Table 22 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)	
	
Figure 2 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)	
	
Bipolar Disorders	
	
Table 23 MARKET SHARES OF MANUFACTURERS PRODUCING DRUGS FOR BIPOLAR DISORDER TREATMENT, 2004 (%)	
	
Figure 3 MARKET SHARES OF MANUFACTURERS PRODUCING BIPOLAR DISORDER DRUGS, 2004 (%)	
	
ADHD Disorders	
	
Table 24 MARKET SHARES OF MANUFACTURERS PRODUCING ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)	
	
Figure 4 MARKET SHARES OF MANUFACTURERS OF ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%)	
	
Autistic Disorders	
	
Table 25 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%)	
	
Figure 5 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%)	
	
Schizophrenia	
	
Table 26 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%)	
	
Figure 6 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%)	
	
Learning Disorders	
	
Table 27 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%)	
	
Figure 7 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%)	
	
Eating Disorders	
	
Table 28 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING EATING DISORDERS, 2004 (%)	
	
Figure 8 MARKET SHARES OF MANUFACTURERS OF DRUGS TO TREAT EATING DISORDERS, 2004 (%)	
	
Conduct Disorders	
	
Table 29 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%)	
	
Figure 9 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%)	
	
MARKET BY DRUG TYPES	
TOTAL MARKET SIZE	
	
Table 30 WORLDWIDE SALES OF DRUGS BY TYPE TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Table 31 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004	
	
Figure 10 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
SALES BY TYPE OF THERAPEUTIC CATEGORY	
	
BENZODIAZEPINES	
	
Table 32 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 11 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)	
	
Table 33 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 12 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
TRICYCLIC ANTIDEPRESSANTS	
	
Table 34 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 13 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
ANTIHISTAMINES	
	
Table 35 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 14 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS	
	
Table 36 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 15 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
MOOD STABILIZERS	
	
Table 37 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 16 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
CNS STIMULANTS	
	
Table 38 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 17 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
NONSTIMULANTS	
	
Table 39 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 18 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
ATYPICAL ANTIPSYCHOTICS	
	
Table 40 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 19 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
MARKET BY DISORDERS	
TOTAL MARKET SIZE	
	
Table 41 WORLDWIDE SALES OF DRUGS BY TYPE OF DISORDER TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Table 42 PERCENTAGE SHARE OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%)	
	
Figure 20 SHARES OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%)	
	
SALES BY TYPE OF DRUGS	
	
ANTIANXIETY AGENTS	
	
Table 43 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 21 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
DRUGS USED TO TREAT DEPRESSION	
	
Table 44 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 22 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
DRUGS USED TO TREAT BIPOLAR DISORDER	
	
Table 45 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 23 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
ADHD DRUGS	
	
Table 46 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 24 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
AUTISTIC DISORDER DRUGS	
	
Table 47 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 25 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
SCHIZOPHRENIA DRUGS	
	
Table 48 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 26 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
DRUGS FOR LEARNING DISORDERS	
	
Table 49 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 27 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
DRUGS FOR EATING DISORDERS	
	
Table 50 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 28 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
CONDUCT DISORDER DRUGS	
	
Table 51 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 29 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
DEMOGRAPHICS	
OVERVIEW	
	
ANTIANXIETY AGENTS	
	
Table 52 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 30 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
ANTIDEPRESSANTS	
	
Table 53 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 31 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
BIPOLAR DISORDER DRUGS	
	
Table 54 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 32 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
ADHD DRUGS	
	
Table 55 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 33 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
AUTISTIC DISORDER DRUGS	
	
Table 56 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 34 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
SCHIZOPHRENIA DRUGS	
	
Table 57 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 35 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
LEARNING DISORDER DRUGS	
	
Table 58 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 36 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
EATING DISORDER DRUGS	
	
Table 59 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 37 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
CONDUCT DISORDER DRUGS	
	
Table 60 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
Figure 38 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%)	
	
NEW DEVELOPMENTS	
NEW DEVELOPMENTS	
	
AstraZeneca	
	
Table 61 NEW DRUGS FROM ASTRAZENECA	
	
Bristol-Myers Squibb	
	
Table 62 NEW DRUGS FROM BRISTOL-MYERS SQUIBB	
	
Celgene	
	
Table 63 NEW DRUGS FROM CELGENE	
	
GlaxoSmithKline	
	
Table 64 NEW DRUGS FROM GLAXOSMITHKLINE	
	
Table 64 (CONTINUED)	
	
Johnson & Johnson	
	
Table 65 NEW DRUGS FROM JOHNSON & JOHNSON	
	
Merck	
	
Table 66 NEW DRUGS FROM MERCK	
	
Novartis	
	
Table 67 NEW DRUGS FROM NOVARTIS	
	
Pfizer	
	
Table 68 NEW DRUGS FROM PFIZER	
	
Roche	
	
Table 69 NEW DRUGS FROM ROCHE	
	
Sanolfi-Aventis	
	
Table 70 NEW DRUGS FROM SANOFI-AVENTIS	
	
Shire	
	
Table 71 NEW DRUGS FROM SHIRE	
	
Solvay	
	
Table 72 NEW DRUGS FROM SOLVAY	
	
Wyeth	
	
Table 73 NEW DRUGS FROM WYETH	
	
PATENTS	
PATENTS BY YEAR	
	
Table 74 ANNUAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2001-2005	
	
Figure 39 TOTAL PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005	
	
Figure 40 ANNUAL SHARE OF PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005 (%)	
	
PATENTS BY CATEGORY	
	
Table 75 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005	
	
Figure 41 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005	
	
Figure 42 SHARE OF TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 (%)	
	
SIGNIFICANT PATENTS OF 2005	
	
Table 76 SIGNIFICANT PATENTS FOR DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS, 2005	
	
PATENTS BY COMPANY	
	
Table 77 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COMPANY, 2001-2005	
	
Table 77 (CONTINUED)	
	
PATENTS BY COUNTRY	
	
Table 78 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS)	
	
Table 78 (CONTINUED)	
	
Figure 43 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS)	
	
Table 79 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2005-2001	
	
Figure 44 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005	
	
Figure 45 SHARE OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005 (%)	
	
PATENTS BY ASSIGNEE	
	
Table 80 NUMBER AND SHARE OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005	
	
Figure 46 NUMBER OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (NUMBER OF PATENTS)	
	
Figure 47 SHARES OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (%)	
	
INTERNATIONAL ASPECTS	
TOTAL MARKET SIZE	
	
Table 81 REGIONAL SALES OF TREATMENTS FOR BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
REGIONAL SALES BY TYPE OF DISORDER	
	
ANTIANXIETY AGENTS	
	
Table 82 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 48 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
ANTIDEPRESSANTS	
	
Table 83 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 49 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
BIPOLAR DISORDER DRUGS	
	
Table 84 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 50 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
ADHD DRUGS	
	
Table 85 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 51 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
AUTISTIC DISORDER DRUGS	
	
Table 86 REGIONAL SALES OF AUTISTIC DISORDER DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 52 REGIONAL SALES OF ADHD DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
SCHIZOPHRENIA DRUGS	
	
Table 87 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 53 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
Learning Disorder Drugs	
	
Table 88 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 54 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
Conduct Disorder Drugs	
	
Table 89 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 55 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
Eating Disorder Drugs	
	
Table 90 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS)	
	
Figure 56 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS)	
	
PREVELANCE OF EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS IN SELECTED COUNTRIES	
	
UNITED STATES	
	
UNITED KINGDOM	
	
INDIA	
	
CHINA	
	
China (Continued)	
	
COMPANY PROFILES	
ABBOTT LABORATORIES	
	
ALLIANT PHARMACEUTICALS	
	
BRISTOL-MYERS SQUIBB	
	
CELEGENE	
	
CELLTECH PHARMACEUTICALS	
	
ELI LILLY	
	
GLAXOSMITHKLINE PLC	
	
JOHNSON & JOHNSON	
	
JOHNSON & JOHNSON (CONTINUED)	
	
MALLINCKRODT MEDICAL	
	
NOVARTIS PHARMACEUTICAL CORP.	
	
OVATION PHARMACEUTICALS	
	
PFIZER, INC.	
	
ROCHE	
	
SHIRE	
	
SOLVAY	
	
VALEANT PHARMACEUTICALS